OBJECTIVE： To observe the clinical efficacy and safety of intravitreal injection of ranibizumab combined with argon laser therapy in the treatment of ischemic neovascular glaucoma. METHODS： A total of 166 patients with neovascular glaucoma selected from our hospital during Mar. 2014-Mar. 2016 were divided into control group and observation group according to random number table， with 88 cases in each group （there were 117 and 125 eyes respectively）. Both groups received argon laser photocoagulation therapy twice a week for 1 month. Observation group was additionally given intravitreal injection of Ranibizumab injection （0.5 mg） once a week， for 1 month. Clinical efficacies of 2 groups were observed， and the intraocular pressure and visual acuity of 2 groups were observed before treatment， 1 week and 1 month after treatment. The occurrence of ADR was recorded. RESULTS： After 1 month of treatment， total response rate was 95.20％ in observation group， which was significantly higher than 76.92％ in control group， with statistical significance （P＜0.05）. After 1 week of treatment， intraocular pressures of observation group were lower than before treatment and control group at the same time， while visual acuity was better than before treatment and control group at the same time， with statistical significance （P＜0.05）. After 1 month of treatment， intraocular pressures of 2 groups were decreased significantly and visual acuity was significantly improved； intraocular pressure was decreased and visual acuity was improved more significantly in observation group than control group， with statistical significance （P＜0.05 or P＜0.01）. The incidences of ADR of 2 groups were 3.41％ and 2.27％， without statistical significance （P＞0.05）. CONCLUSIONS： The ischemic intravitreal injection of ranibizumab combined with argon laser therapy is better than argon laser therapy alone in the treatment of ischemic neovascular glaucoma， and can significantly reduce intraocular pressure and improve visual acuity with good safety.